109 related articles for article (PubMed ID: 11595402)
1. Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Tokinaga N; Inoue Y; Otani K; Kaneko S
Schizophr Res; 2001 Oct; 52(1-2):139-42. PubMed ID: 11595402
[No Abstract] [Full Text] [Related]
2. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
[TBL] [Abstract][Full Text] [Related]
4. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
[TBL] [Abstract][Full Text] [Related]
5. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
6. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.
Suzuki A; Otani K; Mihara K; Yasui N; Kaneko S; Inoue Y; Hayashi K
Pharmacogenetics; 1997 Oct; 7(5):415-8. PubMed ID: 9352580
[No Abstract] [Full Text] [Related]
7. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
8. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
Rao VA; Bishop M; Coppen A
Br J Psychiatry; 1980 Dec; 137():518-21. PubMed ID: 7214106
[TBL] [Abstract][Full Text] [Related]
9. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Otani K; Kaneko S; Inoue Y
Clin Pharmacol Ther; 1999 Mar; 65(3):291-4. PubMed ID: 10096261
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
[TBL] [Abstract][Full Text] [Related]
11. Relationship of the
Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2023 Dec; 53(4):15-22. PubMed ID: 38076663
[TBL] [Abstract][Full Text] [Related]
12. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
13. [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin].
Gu SF
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Dec; 25(6):328-30, 382. PubMed ID: 1304992
[TBL] [Abstract][Full Text] [Related]
14. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
16. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):63-6. PubMed ID: 12107619
[TBL] [Abstract][Full Text] [Related]
18. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
19. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Ono S; Kaneko S; Otani K; Inoue Y
Ther Drug Monit; 2000 Jun; 22(3):245-9. PubMed ID: 10850389
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
